ArticleNature communications2019
Neural JNK3 regulates blood flow recovery after hindlimb ischemia in mice via an Egr1/Creb1 axis.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- The Prognostic and Biological Value of PGF-Based H&E Pathomics in Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- The role of JNK signaling pathway in organ fibrosis.Journal of advanced research · 2025Review
- Endothelial Reactive Oxygen Species: Key Players in Cardiovascular Health and Disease.Antioxidants & redox signaling · 2025Review
- Article
- Identification of potential JNK3 inhibitors through virtual screening, molecular docking and molecular dynamics simulation as therapeutics for Alzheimer's disease.Molecular diversity · 2024Article
- miR-709 exerts an angiogenic effect through a FGF2 upregulation induced by a GSK3B downregulation.Scientific reports · 2024Article
- Enhanced pericyte-endothelial interactions through NO-boosted extracellular vesicles drive revascularization in a mouse model of ischemic injury.Nature communications · 2023Article
- Genetic deletion of c-Jun amino-terminal kinase 3 (JNK3) modestly increases disease severity in a mouse model of multiple sclerosis.Journal of neuroimmunology · 2023Article
- MicroRNA-582-5p targeting Creb1 modulates apoptosis in cardiomyocytes hypoxia/reperfusion-induced injury.Immunity, inflammation and disease · 2022Article
- Construction and investigation of β3GNT2-associated regulatory network in esophageal carcinoma.Cellular & molecular biology letters · 2022Article
- Maternal lead exposure induces sex-dependent cerebellar glial alterations and repetitive behaviors.Frontiers in cellular neuroscience · 2022Article
- Serine 26 in Early Growth Response-1 Is Critical for Endothelial Proliferation, Migration, and Network Formation.Journal of the American Heart Association · 2021Article
- Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice.Frontiers in pharmacology · 2021Article
- MAPK10 Expression as a Prognostic Marker of the Immunosuppressive Tumor Microenvironment in Human Hepatocellular Carcinoma.Frontiers in oncology · 2021Article
- Melatonin-Medicated Neural JNK3 Up-Regulation Promotes Ameloblastic Mineralization.Frontiers in cell and developmental biology · 2021Article
- Review
- PDRPS7 protects cardiac cells from hypoxia/reoxygenation injury through inactivation of JNKs.FEBS open bio · 2020Article
- PLZF and PLZF-MAPK10 can predict the prognosis of postoperative patients with hepatocellular carcinoma.International journal of clinical and experimental pathology · 2020Article
- Systematical Identification of the Protective Effect of Danhong Injection and BuChang NaoXinTong Capsules on Transcription Factors in Cerebral Ischemia Mice Brain.Oxidative medicine and cellular longevity · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Diseases related to impaired blood flow such as peripheral artery disease (PAD) impact nearly 10 million people in the United States alone, yet patients with clinical manifestations of PAD (e.g., claudication and limb ischemia) have limited treatment options. In ischemic tissues, stress kinases such as c-Jun N-terminal kinases (JNKs), are activated. Here, we show that inhibition of the JNK3 (Mapk10) in the neural compartment strikingly potentiates blood flow recovery from mouse hindlimb ischemia. JNK3 deficiency leads to upregulation of growth factors such as Vegfa, Pdgfb, Pgf, Hbegf and Tgfb3 in ischemic muscle by activation of the transcription factors Egr1/Creb1. JNK3 acts through Forkhead box O3 (Foxo3a) to suppress the activity of Egr1/Creb1 transcription regulators in vitro. In JNK3-deficient cells, Foxo3a is suppressed which leads to Egr1/Creb1 activation and upregulation of downstream growth factors. Collectively, these data suggest that the JNK3-Foxo3a-Egr1/Creb1 axis coordinates the vascular remodeling response in peripheral ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.